# OnCo record nifty (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nifty/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nifty", "NCT03524508" ;
  schema:name "NIFTY"@en ;
  schema:description "A Korean trial found that adding liposomal irinotecan to fluorouracil as second-line chemotherapy for bile duct and gallbladder cancer delayed progression, from about six weeks to four months on the re-read scans, at the cost of more neutropenia. A German trial of the same idea was negative, so it is an option rather than a standard, and it is not commissioned in the UK."@en ;
  schema:url <https://onco.cc/trials/nifty/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03524508>, <https://doi.org/10.1016/S1470-2045(21)00486-1>, <https://doi.org/10.1001/jamaoncol.2023.0016> ;
  onco:status "positive" ;
  onco:tag "lesson:replication" ;
  onco:phase "2" ;
  onco:related <https://onco.cc/trials/naliricc/>, <https://onco.cc/trials/abc-06/> ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/leucovorin/> ;
  onco:institutions <https://onco.cc/institutions/asan-medical-center/> ;
  onco:people <https://onco.cc/people/ghassan-abou-alfa/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nifty-liposomal-irinotecan-lancet-oncol-2021/> .